Orchestra BioMed Holdings (OBIO) Gains from Sales and Divestitures (2023 - 2026)
Orchestra BioMed Holdings (OBIO) reported Gains from Sales and Divestitures of $215988.0 for Q1 2026, up 21.15% year-over-year from $178286.0 in Q1 2025, and down 82.17% on a QoQ basis from $1.2 million in Q4 2025.
Orchestra BioMed Holdings (OBIO) has 4 years of Gains from Sales and Divestitures data on file, last reported at $215988.0 in Q1 2026.
- Quarterly Gains from Sales and Divestitures rose 21.15% year-over-year to $215988.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $215988.0 (up 21.15% YoY) and the FY2025 annual result came in at $1.2 million, up 190.93% from the prior year.
- Gains from Sales and Divestitures fell to $215988.0 in Q1 2026 per OBIO's latest filing, from $1.2 million in the prior quarter.
- Across five years, Gains from Sales and Divestitures topped out at $1.2 million in Q4 2025 and bottomed at $13100.0 in Q1 2024.
- The 4-year median for Gains from Sales and Divestitures is $161431.5 (2024), against an average of $330179.5.
- The widest annual swing landed in 2024, when Gains from Sales and Divestitures slumped 64.85%; it then jumped 2704.3% in 2025.
- Tracing OBIO's Gains from Sales and Divestitures over 4 years: stood at $80790.0 in 2023, then surged by 415.37% to $416368.0 in 2024, then jumped by 190.93% to $1.2 million in 2025, then slumped by 82.17% to $215988.0 in 2026.
- Per Business Quant, the three latest OBIO Gains from Sales and Divestitures figures stand at $215988.0 (Q1 2026), $1.2 million (Q4 2025), and $922848.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Orchestra BioMed Holdings | 245.24 Mn | 255.02 Mn | 78,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 215,988.00 |
| Mar 31, 2026 | 215,988.00 |
| Dec 31, 2025 | 1.21 Mn |
| Dec 31, 2025 | 1.21 Mn |
| Sep 30, 2025 | 922,848.00 |
| Sep 30, 2025 | 922,848.00 |
| Jun 30, 2025 | 625,414.00 |
| Jun 30, 2025 | 625,414.00 |
| Mar 31, 2025 | 178,286.00 |
| Mar 31, 2025 | 178,286.00 |
| Dec 31, 2024 | 416,368.00 |
| Dec 31, 2024 | 416,368.00 |
| Sep 30, 2024 | 144,577.00 |
| Sep 30, 2024 | 144,577.00 |
| Jun 30, 2024 | 22,302.00 |
| Jun 30, 2024 | 22,302.00 |
| Mar 31, 2024 | 13,100.00 |
| Mar 31, 2024 | 13,100.00 |
| Dec 31, 2023 | 80,790.00 |
| Dec 31, 2023 | 80,790.00 |
| Sep 30, 2023 | 67,689.00 |
| Sep 30, 2023 | 67,689.00 |
| Jun 30, 2023 | 63,451.00 |
| Jun 30, 2023 | 63,451.00 |